Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

MXCT

Maxcyte (MXCT)

Maxcyte Inc
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:MXCT
DateTimeSourceHeadlineSymbolCompany
08/05/202418:46Alliance NewsAlliance NewsMaxCyte shares rise amid double-digit revenue increaseLSE:MXCTMaxcyte Inc
08/05/202416:05RNS Regulatory NewsMaxCyte, Inc. Filing of Form 10-QLSE:MXCTMaxcyte Inc
08/05/202416:00RNS Regulatory NewsMaxCyte, Inc. First Quarter ResultsLSE:MXCTMaxcyte Inc
03/05/202416:00RNS Regulatory NewsMaxCyte, Inc. Notice of AGMLSE:MXCTMaxcyte Inc
02/05/202402:04RNS Regulatory NewsMaxCyte, Inc. Total Voting RightsLSE:MXCTMaxcyte Inc
10/04/202422:05RNS Regulatory NewsMaxCyte, Inc. Notice of ResultsLSE:MXCTMaxcyte Inc
03/04/202417:00RNS Regulatory NewsMaxCyte, Inc. Total Voting Rights and Block Listing ReturnLSE:MXCTMaxcyte Inc
03/04/202401:19Alliance NewsAlliance NewsTRADING UPDATES: MaxCyte inks deal with Be Bio; Orcadian firms farmoutLSE:MXCTMaxcyte Inc
02/04/202423:05RNS Regulatory NewsMaxCyte, Inc. Signing of Strategic Platform LicenseLSE:MXCTMaxcyte Inc
02/04/202417:00RNS Regulatory NewsMaxCyte, Inc. Exercise of options and PDMR dealingLSE:MXCTMaxcyte Inc
20/03/202421:16RNS Regulatory NewsMaxCyte, Inc. Grant of Options, RSUs and PSUs and PDMR DealingLSE:MXCTMaxcyte Inc
20/03/202421:05RNS Regulatory NewsMaxCyte, Inc. Grant of Options, RSUs and PSUs and PDMR DealingLSE:MXCTMaxcyte Inc
13/03/202422:54Alliance NewsAlliance NewsIN BRIEF: MaxCyte loss widens in 2023 as core revenue declines 25%LSE:MXCTMaxcyte Inc
13/03/202418:05RNS Regulatory NewsMaxCyte, Inc. Filing of form 10-K for FY ended December 31, 2023LSE:MXCTMaxcyte Inc
13/03/202418:00RNS Regulatory NewsMaxCyte, Inc. Reports Q4 & FY 2023 Financial ResultsLSE:MXCTMaxcyte Inc
13/03/202407:05UK RegulatoryMaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 GuidanceLSE:MXCTMaxcyte Inc
06/03/202419:58RNS Regulatory NewsMaxCyte, Inc. TR-1: Notification of major holdingsLSE:MXCTMaxcyte Inc
06/03/202407:43Alliance NewsAlliance NewsEARNINGS: dotdigital eyes rosy future; Beeks Financial turns to profitLSE:MXCTMaxcyte Inc
05/03/202418:00RNS Regulatory NewsMaxCyte, Inc. Preliminary FY Results & 2024 GuidanceLSE:MXCTMaxcyte Inc
05/03/202408:05UK RegulatoryMaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary ResultsLSE:MXCTMaxcyte Inc
02/03/202404:57RNS Regulatory NewsMaxCyte, Inc. Total Voting RightsLSE:MXCTMaxcyte Inc
29/02/202420:21RNS Regulatory NewsMaxCyte, Inc. Exercise of options and PDMR dealingLSE:MXCTMaxcyte Inc
26/02/202418:00RNS Regulatory NewsMaxCyte, Inc. TR-1: Notification of major holdingsLSE:MXCTMaxcyte Inc
10/02/202400:05RNS Regulatory NewsMaxCyte, Inc. Notice of ResultsLSE:MXCTMaxcyte Inc
10/02/202400:05UK RegulatoryMaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor ConferencesLSE:MXCTMaxcyte Inc
01/02/202420:24RNS Regulatory NewsMaxCyte, Inc. Total Voting RightsLSE:MXCTMaxcyte Inc
31/01/202418:00RNS Regulatory NewsMaxCyte, Inc. Director/PDMR ShareholdingLSE:MXCTMaxcyte Inc
31/01/202401:29RNS Regulatory NewsMaxCyte, Inc. Holding(s) in CompanyLSE:MXCTMaxcyte Inc
31/01/202400:58Alliance NewsAlliance NewsIN BRIEF: MaxCyte signs licencing deal with cell therapy company WugenLSE:MXCTMaxcyte Inc
31/01/202400:05UK RegulatoryMaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for CancersLSE:MXCTMaxcyte Inc
 Showing the most relevant articles for your search:LSE:MXCT